Sigma-Tau Industrie Farmaceutiche Riunite S.p.a.

Sciclone Pharmaceuticals, Inc.

Tecnogen S.p.a.

Francesco Bistoni

Luigina Romani

Enrico Garaci

Paolo Carminati

Guido Rasi

Marica Sassano

Paolo Di Francesco

Silvia Bozza

A method for treating a human infected withby using thymosin alpha 1 as an immuno-stimulator in activating dendritic cells. The method is particularly useful in preventing an infection byin an immuno-compromised host being treated with a bone marrow transplantation.

[object Object]

It is described the use of thymosin alpha 1 in combination with long pentraxin PTX3 or Ganciclovir, for the preparation of a medicament for the prevention or treatment of viral diseases and/or for inhibiting virus activation.

Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection

It is described the use of the long pentraxin PTX3 (PTX3) or one of its functional derivatives, for the preparation of a medicament for the prevention or treatment of viral diseases and/or for inhibiting virus activation.

Use of the long pentraxin PTX3 for the prevention or treatment of viral diseases

It is described the use of thymosin alpha 1 for preparing a medicament useful for the prevention or treatment of graft-versus-host disease or graft rejection reactions in organ transplantation, in a mammal subject, in which the cells, tissues or organs for transplant is selected from the group comprising: stem cells, hematopoietic stem cells, bone marrow, heart, liver, kidney, lung, pancreas, small intestine, cornea or skin.

Growing community of inventors

Perugia, Italy

Francesco Bistoni